Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
Earnings Data
Report Date
Mar 04, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.37Last Year’s EPS
-0.29Same Quarter Last Year
Moderate Buy
Based on 16 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call reflected significant progress with the FDA approval of EMPAVELI and strong market leadership of SYFOVRE. However, challenges in SYFOVRE revenue due to free drug programs and operational challenges in patient access were notable concerns.Company Guidance
FDA Approval of EMPAVELI
EMPAVELI was approved for treating patients 12 years and older with C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), expanding the addressable market by approximately 5,000 patients.
SYFOVRE Market Leadership
SYFOVRE maintained its leading position, accounting for an estimated 52% of new patient starts and more than 60% of the overall market.
Strong Financial Performance
Total revenue for the third quarter was $459 million, including a $275 million upfront payment from Sobi.
Positive EMPAVELI Launch Feedback
The market feedback for EMPAVELI has been exceptionally positive, highlighting its ease of use and the convenience of twice-weekly dosing.
Continued Injection Growth for SYFOVRE
SYFOVRE experienced a 4% growth in total estimated injections during the quarter.
APLS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
APLS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 30, 2025 | $30.05 | $20.73 | -31.01% |
Jul 31, 2025 | $19.00 | $22.34 | +17.58% |
May 07, 2025 | $19.12 | $17.99 | -5.91% |
Feb 28, 2025 | $26.00 | $25.15 | -3.27% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Apellis Pharmaceuticals Inc (APLS) report earnings?
Apellis Pharmaceuticals Inc (APLS) is schdueled to report earning on Mar 04, 2026, After Close (Confirmed).
What is Apellis Pharmaceuticals Inc (APLS) earnings time?
Apellis Pharmaceuticals Inc (APLS) earnings time is at Mar 04, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is APLS EPS forecast?
APLS EPS forecast for the fiscal quarter 2025 (Q4) is -0.37.